| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Dyne Therapeutics, Inc. (DYN) has 7 insiders with recent SEC Form 4 filings, including 2 buys and 45 sells. DYN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 5.28M | $110.10M | - | |
| Dir | 1.16M | $24.19M | - | |
| CEO | 368.2K | $7.68M | -2,683 | |
| Other | 169.2K | $3.53M | -887 | |
| Other | 154.2K | $3.22M | -145 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2024 | Atlas Venture Fund Xi, L.P.53 | 10% Owner | Sell | 807,838 | $24.30 | $19,626,902.97 | -1.6% | +20.1% | -47.3% | |
| Feb 23, 2024 | Rhodes Jason P78 | Director | Sell | 500,789 | $22.64 | $11,339,780.44 | -1.7% | +37.1% | -38.5% | |
| Feb 23, 2024 | Atlas Venture Fund Xi, L.P.53 | 10% Owner | Sell | 500,789 | $22.64 | $11,339,780.44 | -1.7% | +37.1% | -38.5% | |
| Feb 20, 2024 | Rhodes Jason P78 | Director | Sell | 510,152 | $23.26 | $11,867,292.26 | -1.4% | +55.6% | -39.2% | |
| Feb 20, 2024 | Atlas Venture Fund Xi, L.P.53 | 10% Owner | Sell | 510,152 | $23.26 | $11,867,292.26 | -1.4% | +55.6% | -39.2% | |
| Feb 12, 2024 | Farwell Wildon55 | Chief Medical Officer | Sell | 5,493 | $25.07 | $137,709.51 | -3.3% | +9.5% | -44.4% | |
| Jan 26, 2024 | Scalzo Richard William58 | SVP, Head Of Finance &Admin. | Sale+OE | 13,000 | $24.34 | $316,420.00 | -9.5% | +12.0% | -35.2% | |
| Jan 26, 2024 | Farwell Wildon55 | Chief Medical Officer | Sell | 100 | $25.00 | $2,500.00 | - | +12.0% | -35.2% | |
| Jan 26, 2024 | McNeill Jonathan55 | Chief Business Officer | Sale+OE | 20,000 | $24.53 | $490,510.36 | -6.5% | +12.0% | -35.2% | |
| Jan 9, 2024 | Kersten Dirk87 | Director, 10% Owner | Buy | 1,714,285 | $17.50 | $29,999,987.50 | +28.0% | +43.3% | +22.8% |